Pharvaris N.V.
PHVSDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
3
Next Catalyst
Aug 11, 2026
7dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
PHVS Earnings Report
EPS Est: $-0.74 | FQ end 2026-06
Deucrictibant Phase 3 Est. Readout
Primary completion for Deucrictibant trial (NCT06669754) in Hereditary Angioedema (HAE)
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Deucrictibant | Phase 3 | Hereditary Angioedema | - | - |
Deucrictibant low dose | Phase 2 | Hereditary Angioedema | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Pharvaris N.V.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Pharvaris N.V.'s (PHVS) pipeline across Phase 3, Phase 2. Its lead program is Deucrictibant (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Pharvaris N.V.'s next FDA catalyst?→
Pharvaris N.V.'s (PHVS) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PHVS biotech catalysts?→
Add PHVS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pharvaris N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.